PrecisemAb Biotech is a research-driven biotechnology company pioneering tumor-selective antibody therapeutics through its proprietary Antibody Lock Platform.
Our mission is to advance a new generation of safer and more precise biologics that minimize systemic toxicity while maintaining strong anti-tumor efficacy.
With a growing pipeline of preclinical and clinical-stage programs, PrecisemAb aims to redefine the therapeutic index of antibody-based medicines and create sustainable value for patients, partners, and investors.
Investor Relations
PrecisemAb Biotech is a preclinical-stage biotechnology company focused on developing tumor-selective and conditionally activated antibody therapeutics through its proprietary Antibody Lock Technology Platform. This platform is designed to keep antibodies inactive in normal tissues and selectively activated within tumor or disease microenvironments, achieving an optimal balance of precision, safety, and efficacy.
The company is advancing several antibody programs driven by tumor-selective activation, including PSM101, a tumor-activated anti-EGFR antibody, and PSM915, an immune-modulating antibody candidate, while expanding its applications to bispecific antibodies (Lock BsAb) and antibody-drug conjugates (Lock ADC).
Guided by the belief that effective and safe treatments empower patients with the courage to fight illness, PrecisemAb is redefining how biologics perform in the body and shaping a new generation of intelligent antibody therapies. Our mission extends beyond innovation—we aim to create lasting value for patients, partners, and investors by advancing safer and smarter biologic medicines.
Partner with Precisemab to unlock the potential of Antibody Lock Technology.
We collaborate with biotechnology and pharmaceutical partners to co-develop tumor-activated antibodies, bispecifics, and ADCs, enabling new therapeutic strategies in oncology and immune modulation.
Our expertise spans from molecular design to preclinical validation, ensuring rapid translation from concept to candidate.
We welcome strategic alliances that leverage our technology platform to create safer, more effective antibody therapeutics for patients worldwide.
Together for Better Treatments
We work with partners to achieve innovative drug solutions for patients.
What Issues We Are Working On
Monoclonal antibodies have become a trend because of their therapeutic efficacy. However, long-term use of traditional antibody drugs might cause severe side effects because of on-target toxicity. PrecisemAb looks to address this issue by providing safer antibody drugs for patients with higher drug selectivity in the disease region. Because we deeply believe that.Only when treatments are both effective and safe would patients have the courage and persistence to fight illness.
How We Solve the Problem
Our technology, Universal Antibody Lock, improves the safety of antibody drugs by ensuring they activate in disease areas rather than healthy tissues. The technology applies to all antibody drugs, and we have recently shown it is applicable for autoimmune disease, oncology, immunotherapy, and antibody drug conjugates.
What are the Applications
With the antibody lock technology, we can enhance existing drugs with higher safety, resurrect products withdrawn from the market due to high toxicity, and make new drugs with patent-expiring antibodies.
Together, We Can Make a Better Future
PrecisemAb is now actively seeking strategic partnerships for realizing our mission of developing safer antibody therapies for patients.
Our partnering opportunities include
PrecisemAb Developed Antibody Out-Licensing
Customized Lock-Design Service
Join Us
Building a Healthier Future Together
Our Partners
